Loading...
•
Mar 31, 2022
Sight Sciences Q1 2022 Earnings Report
Reported financial results, demonstrating revenue growth and expanded gross margin.
Key Takeaways
Sight Sciences reported a strong first quarter with a 72% increase in revenue compared to the prior year period, driven by growth in both Surgical Glaucoma and Dry Eye segments. The company also expanded its gross margin to 80%.
Total revenue increased by 72% to $14.9 million compared to the prior year period.
The number of facilities ordering the OMNI® Surgical System increased from 760 to 811.
The installed base of TearCare® facilities grew from 562 to 635.
Gross margin expanded to 80% compared to 73% in the prior year period.
Revenue by Segment
Forward Guidance
Sight Sciences projects full year 2022 revenue to range from $67 million to $75 million, representing growth of approximately 37% to 53% compared to 2021.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...